Cell-Based MS Drug Screening

Label-free, direct measurement of drug effects in living cells — metabolomics, drug uptake, single-cell profiling, organoid models, and resistance mechanism analysis from a single service platform.

Cell-based mass spectrometry (MS) drug screening is a label-free analytical approach that directly measures drug effects in living cellular systems, providing physiologically relevant pharmacology data that bridges in vitro biochemistry and in vivo efficacy. Unlike conventional biochemical assays that use purified targets in artificial buffer systems, cell-based MS captures the full biological context of drug action — including cell permeability, intracellular metabolism, target engagement, and downstream pathway modulation — from a single experimental workflow.

Our platform integrates 16 specialized service modules covering the entire spectrum of cellular pharmacology: cellular metabolomics and lipidomics screening, drug uptake and retention measurement, intracellular accumulation quantification, metabolic pathway drug-response mapping, organoid and precision-cut tissue slice (PCLS) MS analysis, single-cell drug profiling, patch-clamp MS coupling, apoptosis and cell death pathway MS signatures, immunometabolism profiling, cytokine quantification, drug-resistance mechanism elucidation, and live-cell MS analysis.

Key capabilities of our cell-based MS drug screening platform:

16 specialized service modules covering the full cellular pharmacology spectrum
Label-free detection — no fluorescent tags, antibodies, or radioactive isotopes required
Simultaneous drug quantitation + metabolomic/lipidomic response from a single sample
Support for cell lines, primary cells, 3D spheroids, organoids, and tissue slices
Validated protocols for over 50 cell types with full method development support
From early hit profiling through lead optimization and mechanism-of-action studies

Submit Your Cell-Based MS Screening Project Explore our 16 service modules

Cell-based mass spectrometry drug screening platform showing 16 integrated service modules for label-free cellular pharmacology analysis in drug discovery.

Overview Workflow Service Portfolio Technical Advantages Case Study Sample Requirements FAQ

Overview of Cell-Based Mass Spectrometry Drug Screening

Cell-based MS drug screening directly measures drug effects in living cellular systems, providing physiologically relevant pharmacology data that bridges in vitro biochemistry and in vivo efficacy. Unlike conventional biochemical assays that use purified targets in artificial buffer systems, cell-based MS captures the full biological context of drug action — including cell permeability, intracellular metabolism, target engagement, and downstream pathway modulation — from a single experimental workflow.

We support a wide range of cellular models including immortalized cell lines, primary cells, 3D spheroids, patient-derived organoids, and tissue slices, ensuring that the biological context matches the specific research question. Our validated protocols cover over 50 cell types, and our team provides full method development support for novel cell models.

Cellular Metabolomics & Lipidomics

Cellular metabolomics screening — untargeted and targeted metabolomics to profile drug-induced metabolic perturbations
Cellular lipidomics drug profiling — comprehensive lipid class and species-level analysis of drug effects on cellular lipid metabolism
Metabolic pathway drug-response mapping — stable isotope tracing (SIT-DIMS) to quantify metabolic flux changes upon drug treatment

Drug Permeability & Intracellular PK

Cell permeability MS — direct measurement of compound permeation across cellular membranes using LC-MS/MS
Drug uptake and retention MS — quantitative analysis of intracellular drug accumulation and retention kinetics
Intracellular accumulation MS — time-course measurement of unbound intracellular drug concentrations

Advanced Cellular Models

Organoid metabolomics — MS-based metabolic profiling of patient-derived and stem cell-derived organoids
Tissue slice (PCLS) MS drug response — ex vivo drug response analysis in precision-cut tissue slices preserving native tissue architecture
Single-cell MS drug profiling — single-cell resolution metabolomics and lipidomics to reveal cellular heterogeneity in drug response

Cell Death & Immunometabolism

MS-based apoptosis markers — quantification of apoptotic metabolite and lipid signatures
Cell death pathway MS signatures — profiling of necroptosis, ferroptosis, and pyroptosis markers by MS
Immunometabolism MS profiling — analysis of metabolic reprogramming in immune cells upon drug treatment
Cytokine MS quantification — multiplexed, label-free quantification of cytokine secretion

Drug Resistance & Specialized Techniques

Drug-resistance mechanism MS — metabolomic and lipidomic characterization of acquired and intrinsic resistance mechanisms
Live-cell MS profiling — real-time or near-real-time metabolic monitoring of drug-treated cells
Patch-clamp MS coupling — integrated electrophysiology and MS for ion channel drug profiling

Our Cell-Based MS Drug Screening Workflow

A standardized, quality-controlled process from project scoping to final report. Each project is tailored to the specific cell model, drug compound, and research question.

Cell Culture and Drug Treatment

Cells are cultured under optimized conditions (2D monolayers, 3D spheroids, or organoid cultures) and treated with test compounds at specified concentrations and time points. We support multiwell plate formats (96-well and 384-well) for medium-throughput screening, with automated liquid handling available for larger campaigns. Drug treatment conditions are optimized for each cell type and compound class, including appropriate vehicle controls (typically ≤0.1% DMSO) and positive controls.

Sample Preparation and Metabolite Extraction

Following drug treatment, cells are rapidly quenched to arrest metabolic activity, and intracellular metabolites and lipids are extracted using validated solvent systems. For drug uptake and retention measurements, cells are washed thoroughly to remove extracellular compound, then lysed for LC-MS/MS analysis. For metabolomics and lipidomics, we use biphasic extraction methods (e.g., MTBE/MeOH/H2O or MeOH/CHCl3/H2O) to maximize coverage of both polar metabolites and non-polar lipids. Sample preparation includes appropriate internal standards for quantification.

Mass Spectrometry Acquisition

Depending on the service module, we employ one or more MS platforms: LC-MS/MS (QqQ) for targeted quantification with MRM transitions; LC-HRMS (Q-TOF or Orbitrap) for untargeted metabolomics and lipidomics; MALDI-TOF/TOF for rapid whole-cell profiling; direct-infusion MS (DIMS) for high-throughput metabolic phenotyping with stable isotope tracing; and RapidFire MS for high-speed solid-phase extraction coupled with MS at <15 seconds per sample.

Data Processing and Feature Detection

Raw MS data are processed using industry-standard software (XCMS, MZmine, Compound Discoverer, LipidSearch, Skyline) for peak detection, alignment, and feature extraction. For targeted assays, MRM data are integrated and quantified against calibration curves. For untargeted approaches, features are filtered by quality metrics (CV <30% in QC samples, signal-to-noise >10) before statistical analysis.

Statistical Analysis and Pathway Mapping

Processed data undergo multivariate statistical analysis including PCA, PLS-DA, and OPLS-DA for pattern recognition, as well as univariate analysis (t-test, ANOVA, fold-change) for significant feature identification. Metabolic pathway enrichment analysis is performed using KEGG, HMDB, and Reactome databases. For stable isotope tracing experiments, metabolic flux analysis (MFA) quantifies pathway-level changes in carbon or nitrogen utilization.

Biological Interpretation and Report

A comprehensive report is delivered including: experimental design summary, quality control metrics, differential metabolite/lipid lists with statistical significance, pathway enrichment results, drug response curves (IC50/EC50 where applicable), and biological interpretation in the context of the drug's proposed mechanism of action. Our bioinformatics team is available for follow-up data discussions.

Cell-based MS drug screening workflow diagram showing six steps from cell culture and drug treatment through sample preparation, MS acquisition, data processing, statistical analysis, and final report delivery.

Comprehensive Service Portfolio

Our cell-based MS drug screening platform comprises 16 specialized service modules, organized into logical categories. Click each module to learn more about the specific service.

Cellular Metabolomics Screening

Untargeted and targeted metabolomics analysis of drug-treated cells to identify metabolic perturbations, biomarker candidates, and mechanism-of-action signatures. Coverage includes amino acids, organic acids, nucleotides, sugars, and central carbon metabolism intermediates.

Cellular Lipidomics Drug Profiling

Comprehensive lipid analysis covering major lipid classes (phospholipids, sphingolipids, glycerolipids, sterols, and fatty acids) at the species level. Quantifies drug-induced lipid remodeling and identifies lipid-based pharmacodynamic biomarkers.

Metabolic Pathway Drug-Response Mapping

Stable isotope tracing (13C-glucose, 13C-glutamine, 13C-palmitate) combined with direct-infusion MS to map metabolic flux changes upon drug treatment. Reveals pathway-level mechanism of action and metabolic vulnerabilities.

Cell Permeability MS

Direct measurement of compound permeability across cellular membranes using LC-MS/MS quantification of intracellular drug concentrations. Provides permeability coefficients (Papp) and intracellular free fractions.

Drug Uptake and Retention MS

Quantitative time-course analysis of drug accumulation and retention in target cells. Distinguishes rapidly effluxed compounds from those with sustained intracellular retention.

Intracellular Accumulation MS

High-sensitivity quantification of unbound intracellular drug concentrations using equilibrium dialysis or ultrafiltration coupled with LC-MS/MS. Critical for understanding the relationship between extracellular exposure and intracellular target engagement.

Organoid Metabolomics

MS-based metabolic profiling of patient-derived organoids (PDOs), stem cell-derived organoids, and tumor organoids. Enables drug response assessment in models that recapitulate native tissue architecture and cellular heterogeneity.

Tissue Slice (PCLS) MS Drug Response

Ex vivo drug response analysis in precision-cut lung, liver, kidney, and tumor tissue slices. Preserves tissue microenvironment, cell-cell interactions, and extracellular matrix for more predictive pharmacology data.

Single-Cell MS Drug Profiling

Single-cell resolution metabolomics and lipidomics using MALDI-MS, nano-DESI MS, or capillary microsampling MS. Reveals cell-to-cell heterogeneity in drug response that is masked by bulk analysis.

MS-Based Apoptosis Markers

Quantification of apoptosis-specific metabolite and lipid signatures including ceramides, cardiolipins, oxidized phospholipids, and caspase-cleaved metabolite markers.

Cell Death Pathway MS Signatures

Profiling of regulated cell death pathways (apoptosis, necroptosis, ferroptosis, pyroptosis) by MS-based detection of pathway-specific metabolite and lipid biomarkers.

Live-Cell MS Profiling

Real-time or near-real-time metabolic monitoring of drug-treated cells using microfluidic MS interfaces or direct sampling probes. Captures dynamic metabolic responses that are lost in endpoint measurements.

Immunometabolism MS Profiling

Analysis of metabolic reprogramming in immune cells (T cells, macrophages, dendritic cells, NK cells) upon drug treatment. Covers glycolysis, oxidative phosphorylation, fatty acid oxidation, and glutaminolysis.

Cytokine MS Quantification

Multiplexed, label-free quantification of cytokine secretion using LC-MRM-MS. Complements ELISA and multiplex bead assays with broader analyte coverage and no antibody cross-reactivity.

Drug-Resistance Mechanism MS

Metabolomic and lipidomic characterization of acquired and intrinsic drug resistance mechanisms. Identifies metabolic vulnerabilities that can be therapeutically targeted to overcome resistance.

Patch-Clamp MS Coupling

Integrated electrophysiology (patch-clamp) and MS analysis for simultaneous measurement of ion channel activity and intracellular metabolomic changes in single cells.

Key Technical Advantages

Cell-based MS drug screening offers several distinct advantages over conventional cell-based assay technologies:

Parameter	Cell-Based MS	Fluorescence/HTRF Assays	Radiolabeled Uptake Assays
Label requirement	None (label-free)	Requires fluorescent tags or antibodies	Requires radioactive isotopes
Multiplexing	Unlimited (full metabolome + lipidome + drug quant)	Limited by spectral overlap (2-6 channels)	Single analyte per assay
Cellular context	Full biological context (live cells, organoids, tissue)	Live cells, but limited readout	Live cells, single readout
Drug quantitation	Direct (intracellular drug concentration)	Indirect (reporter signal)	Direct but requires radiolabeled compound
Metabolite coverage	Broad (100s-1000s of features)	None	None
Single-cell capability	Yes (MALDI, nano-DESI, capillary MS)	Limited (flow cytometry)	No
Throughput	Medium (100s-1000s samples/day via RapidFire/MALDI)	High (10,000s/day)	Low-Medium
Cost per sample	Moderate	Low-Moderate	High (isotope cost + disposal)
Data dimensionality	High (multi-parametric)	Low (single-parameter)	Low (single-parameter)

Selection strategy: Cell-based MS is the method of choice when the research question demands multi-parametric data — simultaneous drug uptake, metabolism, and cellular response — from physiologically relevant cellular models. It is particularly valuable for mechanism-of-action studies, drug resistance characterization, and early ADME profiling where understanding the relationship between intracellular drug exposure and pharmacological response is critical. For ultra-high-throughput primary screening of large compound libraries (>100,000 compounds), fluorescence-based assays remain more practical, but cell-based MS serves as an ideal secondary and orthogonal screening platform.

Case Study — Whole-Cell MALDI MS for Lipid Drug-Response Marker Analysis

Weigt D, Sammour DA, Ulrich T, Munteanu B, Hopf C. "Automated analysis of lipid drug-response markers by combined fast and high-resolution whole cell MALDI mass spectrometry biotyping." Scientific Reports 8:11260 (2018). https://doi.org/10.1038/s41598-018-29677-z

Background

Monitoring cellular drug responses at the molecular level is essential for understanding drug mechanism of action and identifying pharmacodynamic biomarkers. Traditional approaches rely on targeted assays that measure predefined endpoints, limiting the discovery of unexpected response markers. Weigt et al. (2018) developed a combined approach using fast whole-cell MALDI-TOF MS biotyping and high-resolution MALDI-FT-ICR MS to identify and validate lipid drug-response markers in a label-free, untargeted manner.

Methods

K562 chronic myeloid leukemia cells were treated with the BCR-Abl inhibitor imatinib at concentrations ranging from 0.01 to 10 µM for 48 hours. Whole-cell MALDI-TOF MS was performed directly on cell suspensions spotted onto a MALDI target plate, acquiring over 2,000 mass features per spectrum in the m/z range of 400-1,000. Principal component analysis (PCA) was used to visualize drug-induced metabolic changes. Candidate response markers were identified by ultra-high-resolution MALDI-FT-ICR MS/MS. The method was further validated across four BCR-Abl inhibitors: imatinib, dasatinib, nilotinib, and ponatinib.

Results

PCA clearly separated imatinib-treated cells from vehicle controls at concentrations as low as 0.1 µM, demonstrating the sensitivity of whole-cell MALDI MS fingerprinting for detecting drug responses. Two dominant response markers were identified and structurally confirmed by FT-ICR MS/MS: heme B (protoporphyrin IX iron complex, [M+H]+ at m/z 616.1766) showed a concentration-dependent decrease with an apparent IC50 of approximately 0.3 µM, while a potassium adduct of phosphatidylcholine PC(36:1) ([M+K]+ at m/z 826.5722) showed a reciprocal increase. The reciprocal regulation of heme B and PC(36:1) was consistent across all four BCR-Abl inhibitors tested, indicating a class-level pharmacodynamic response. The whole-cell MALDI-TOF MS method achieved a throughput of approximately 1 sample per 10 seconds, enabling analysis of multi-concentration drug response curves in a single experimental session.

Conclusions

This study demonstrates that whole-cell MALDI MS biotyping is a rapid, label-free, and information-rich approach for profiling cellular drug responses. The identification of heme B and PC(36:1) as pharmacodynamic markers of BCR-Abl inhibition illustrates the power of untargeted MS-based cellular phenotyping to reveal unexpected response biomarkers. The combined workflow — fast MALDI-TOF screening followed by high-resolution FT-ICR MS for marker identification — provides a template for cell-based MS drug screening that is directly applicable to early drug discovery and lead optimization.

Whole-cell MALDI MS biotyping workflow showing K562 cell treatment with BCR-Abl inhibitors, MALDI-TOF MS acquisition, PCA separation of drug-treated vs control cells, and identification of heme B and PC(36:1) as lipid drug-response markers (adapted from Weigt et al. 2018, Scientific Reports).

Adapted from Weigt et al. (2018): Whole-cell MALDI MS biotyping workflow. K562 cells treated with imatinib (0.01-10 µM) were analyzed by MALDI-TOF MS, with PCA clearly separating treated from control cells at ≥0.1 µM. Heme B (m/z 616.18) and PC(36:1) K+ adduct (m/z 826.57) were identified as pharmacodynamic markers of BCR-Abl inhibition.

Sample Requirements for Cell-Based MS Screening

Sample requirements vary depending on the cell type, culture format, and specific service module. Use the table below as a general guide, and contact our team for project-specific recommendations.

Cell Type	Culture Format	Recommended Seeding Density	Drug Treatment Duration	Minimum Cell Number per Sample	Recommended Replicates
Adherent cell lines (e.g., HepG2, HEK293)	96-well plate	1 × 10⁰ cells/well	24-72 h	5 × 10⁰ cells	3 biological replicates
Suspension cells (e.g., K562, Jurkat)	96-well plate	2 × 10⁰ cells/well	6-48 h	1 × 10⁲ cells	3 biological replicates
Primary cells (e.g., PBMCs, hepatocytes)	96-well plate	5 × 10⁰ cells/well	4-24 h	2 × 10⁲ cells	3 biological replicates
3D spheroids	96-well ULA plate	500-2,000 cells/spheroid	24-72 h	20-50 spheroids	3 biological replicates
Patient-derived organoids	96-well ULA plate	100-500 organoids/well	24-96 h	50-100 organoids	3 biological replicates
Tissue slices (PCLS)	24-well plate	1 slice/well (200-300 µm thick)	4-48 h	3-5 slices	3 biological replicates
Single-cell MS	Custom slide/chip	1 cell/analysis	Variable	50-200 single cells	N/A (single-cell resolution)

Notes: Sample requirements may vary depending on the specific service module, drug compound properties, and desired detection limits. Please contact our team for project-specific recommendations.

Bioinformatics and Data Analysis

Our bioinformatics pipeline for cell-based MS drug screening data is designed to extract maximum biological insight from complex multi-dimensional datasets:

Data Processing

Raw MS data are processed using platform-optimized workflows. For LC-MS metabolomics, we use XCMS-based feature detection with retention time alignment and gap-filling. For lipidomics, LipidSearch and MS-DIAL provide lipid class-specific identification and quantification. For targeted drug quantification, Skyline processes MRM data with automated peak integration and quality control.

Statistical Analysis

We apply a tiered statistical approach: univariate analysis (Student's t-test, ANOVA, Mann-Whitney U test with FDR correction); multivariate analysis (PCA, PLS-DA, OPLS-DA); dose-response modeling (four-parameter logistic regression for IC50/EC50); and time-course analysis (linear mixed-effects models or two-way ANOVA).

Pathway and Network Analysis

Significant metabolite and lipid features are mapped to metabolic pathways using KEGG, HMDB, and LipidMAPS databases. Pathway enrichment analysis identifies the most affected metabolic processes. For stable isotope tracing experiments, metabolic flux analysis (MFA) quantifies carbon and nitrogen flow through central metabolic pathways.

Data Visualization & Accessibility

Deliverables include PCA score plots, heatmaps with hierarchical clustering, volcano plots, metabolic pathway maps with overlaid fold-changes, drug response curves, and time-course trajectory plots. All visualizations are publication-ready. Processed data are delivered in standard formats (Excel, CSV) compatible with MetaboAnalyst, GraphPad Prism, and R.

FAQ

Frequently Asked Questions

Q: What types of cells can be used for cell-based MS drug screening?

We support a wide range of cell types including immortalized cell lines (e.g., HepG2, HEK293, K562, A549, MCF-7), primary cells (hepatocytes, PBMCs, macrophages, neurons), 3D spheroids, patient-derived organoids, and precision-cut tissue slices. Our team can develop custom protocols for novel cell models upon request.

Q: How many compounds can be screened in a single experiment?

Throughput depends on the service module. For targeted drug uptake quantification using RapidFire MS, we can process up to 1,000 samples per day. For untargeted metabolomics using LC-HRMS, typical throughput is 50-100 samples per batch. For whole-cell MALDI-TOF fingerprinting, we achieve approximately 1 sample per 10 seconds. We can scale throughput based on project requirements.

Q: Can you measure both drug uptake and cellular response from the same sample?

Yes. Our integrated workflow allows simultaneous measurement of intracellular drug concentration (by LC-MS/MS) and metabolomic/lipidomic response (by LC-HRMS or MALDI-MS) from the same cell lysate. This enables direct correlation between drug exposure and pharmacological effect within each sample.

Q: What is the detection limit for intracellular drug quantification?

Typical detection limits for intracellular drug quantification range from 0.1 to 10 ng per million cells, depending on the compound's ionization efficiency and the MS platform used. For highly ionizable compounds analyzed by LC-MS/MS with MRM, detection limits can reach 0.01 ng per million cells.

Q: Do you support 3D organoid and tissue slice samples?

Yes. We have established protocols for metabolomic and lipidomic analysis of patient-derived organoids, stem cell-derived organoids, and precision-cut tissue slices (lung, liver, kidney, tumor). These models preserve native tissue architecture and cell-cell interactions, providing more physiologically relevant drug response data than 2D monolayer cultures.

Q: How does cell-based MS compare with traditional fluorescence-based cell assays?

Cell-based MS is label-free, provides multi-parametric data (drug quantitation + metabolomics + lipidomics from one sample), and offers broader coverage of cellular response pathways. Fluorescence-based assays offer higher throughput and lower per-sample cost but are limited to predefined endpoints and require labels that may interfere with cellular physiology. Cell-based MS is ideal for mechanism-of-action studies, resistance profiling, and orthogonal validation of screening hits.

References

Unger MS, Blank M, Enzlein T, Hopf C. Label-free cell assays to determine compound uptake or drug action using MALDI-TOF mass spectrometry. Nature Protocols 16:5533-5558 (2021). doi:10.1038/s41596-021-00624-z. https://doi.org/10.1038/s41596-021-00624-z
Tajik M, Baharfar M, Donald WA. Single-cell mass spectrometry. Trends in Biotechnology 40(11):1374-1392 (2022). doi:10.1016/j.tibtech.2022.04.004. https://doi.org/10.1016/j.tibtech.2022.04.004
Kostidis S, Sánchez-López E, Giera M. Lipidomics analysis in drug discovery and development. Current Opinion in Chemical Biology 72:102256 (2023). doi:10.1016/j.cbpa.2022.102256. https://doi.org/10.1016/j.cbpa.2022.102256
Talaty NN, Johnson RW, Sawicki J, Nacham O, Djuric SW. Recent Developments in Mass Spectrometry to Support Next-Generation Synthesis and Screening. ACS Medicinal Chemistry Letters 14(6):764-775 (2023). doi:10.1021/acsmedchemlett.3c00040. https://doi.org/10.1021/acsmedchemlett.3c00040

Plan your cell-based MS drug screening study with the MassTarget team

Tell us about your cell model, drug compound, and research questions — our scientists will recommend the optimal MS-based approach and design a tailored study for your drug discovery program.

Start your cell-based MS screening inquiry

For research use only. Not for use in diagnostic procedures. Creative Proteomics provides cell-based MS drug screening services exclusively for research and development purposes. Results are not intended for clinical diagnosis or medical decision-making.

Online Inquiry

Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to for inquiries.